printemailclick to share buttonfacebooktwitterlinkedin
Head and Neck Cancer Evidence-based Series (EBS) and Practice Guidelines (PG)

Head and neck cancers include the tongue, mouth, and throat.

The Head & Neck Cancer Disease Site Group (Head & Neck Cancer DSG) produces evidence-based reports to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. The titles of the reports produced to date by the DSG are listed below, with links to the PDF versions of those reports.

The PEBC has a formal and standardized process to ensure the currency of each document. This process guides clinical experts to assess a document’s current status and relevance (please see the PEBC Assessment & Review Protocol for more information). A final status statement is added to the document when this review process is complete. The current status of each guidance document is noted beside the title and link as outlined below:

  • Documents listed as CURRENT are 3 years old or less, up-to-date, and can be used for decision making.
  • Documents listed as IN REVIEW are undergoing assessment for currency and relevance.  The DSG/GDG has determined that it is still appropriate for this document to continue to be available while this updating process unfolds.
  • Documents that are listed as “FOR EDUCATION AND INFORMATION PURPOSES” are documents for which no further updates are planned and whose recommendations may no longer be consistent with recent evidence.  They may be of educational, historical, clinical, or system interest.

If you have any questions regarding a document that is “In Review,” please contact the PEBC ( ) or the lead author of the document.

  • Cancer Care Ontario Thyroid Cancer Guideline: An Endorsement of the 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer
    Guideline 5-13: March 2017
    Status: CURRENT
  • Systemic Therapy in the Curative Treatment of Head and Neck Squamous Cell Cancer
    Guideline 5-11: August 2016
    Status: CURRENT
  • Routine HPV Testing in Head and Neck Squamous Cell Carcinoma
    5-9 EBS: May 2013
    Status: CURRENT
  • The Role of Endolaryngeal Surgery (With or Without Laser) versus Radiotherapy in the Management of Early (T1) Glottic Cancer
    5-2 EBS: March 2012
    Status: CURRENT
  • Epidermal Growth Factor Receptor (EGFR) Targeted Therapy in Stage III and IV Head and Neck Cancer
    5-12 EBS Version 3: March 2015 
    Status: CURRENT
  • The Management of Head and Neck Cancer in Ontario 
    5-3 PG: May 2009
    Status: IN REVIEW
  • Chemotherapy with Radiotherapy for Nasopharyngeal Cancer
    5-7 EBS Version 2: April 2013
    Status: CURRENT

    For Education and Information Purposes 

    • The Role of Post-operative Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck
      5-10 EBS
      The original guideline 5-10 has been replaced by 5-11 Systemic Therapy in the Curative Treatment of Head and Neck Squamous Cell Cancer
      5-10 is available upon request at
    • Symptomatic Treatment of Radiation-Induced Xerostomia in Head and Neck Cancer Patients
    • The Role of Neoadjuvant Chemotherapy in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Excluding Nasopharynx)
    • Concomitant Chemotherapy and Radiotherapy in Squamous Cell Head and Neck Cancer (Excluding Nasopharynx)
      5-6a PG
      The original guideline is available upon request at
    • Hyperfractionated Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
    • Accelerated Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
    • Optimum Radiation Fractionation for T1 NO Glottic (Vocal Cord) Carcinoma
    • The Role of Amifostine as a Radioprotectant in the Management of Patients with Squamous Cell Head and Neck Cancer
    Program in Evidence-Based Care (PEBC)
    McMaster University, Juravinski Site
    G Wing, 2nd Floor
    711 Concession Street
    Hamilton, Ontario, Canada
    L8V 1C3

    Phone: 905.527.4322 ext. 42822
    Fax: 905.526.6775
Last modified: Fri, Mar 31, 2017
cancer care ontario | action cancer ontario   620 University Avenue Toronto Ontario, Canada M5G 2L7   Phone: 416.971.9800 Fax: 416.971.6888

Please help improve the quality of our website by answering 10 brief questions in our online survey. Would you like to participate?